Prime Medicine
Barrett Nehilla has a diverse and extensive work experience. Barrett is currently in the role of Sr. Director, Cell Therapy Process Development & Head of CMC Portfolio Management at Prime Medicine, Inc. Barrett previously worked at Repertoire Immune Medicines, where they held multiple positions, including Senior Director, Analytical Development and Quality Control, Director, Analytical Development & Quality Control, and Associate Director, Analytical Development & Quality Control. Before that, they worked as a Principal Scientist at Mersana Therapeutics.
In academia, Barrett held roles at the University of Washington, where they served as an Affiliated Assistant Professor in the Department of Bioengineering and as a Senior Fellow. Barrett also worked at Nexgenia, Inc as a Senior Scientist and Scientist. Prior to that, they were a Postdoctoral Research Associate at the University of Rochester. Moreover, Barrett has experience in teaching as an Instructor at Rochester Pre-College Programs.
Barrett's career began as a Graduate Research Assistant at Boston University, where they contributed to research projects. Overall, their work experience showcases their expertise in areas such as cell therapy process development, analytical development, quality control, bioengineering, and scientific research.
Barrett Nehilla received a Bachelor of Science degree in Biomedical Engineering from the University of Rochester from 1998 to 2002. Following this, they pursued a PhD in Biomedical Engineering & Pharmacology from Boston University, completing their studies from 2002 to 2008.
This person is not in any teams
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.